FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2768245655> ?p ?o ?g. }

• W2768245655 endingPage "935.e9" @default.
• W2768245655 startingPage "923" @default.
• W2768245655 abstract "BackgroundAdding tiotropium to existing inhaled corticosteroid (ICS) maintenance therapy with or without a long-acting β2-agonist (LABA) has been shown to be beneficial in patients with symptomatic asthma.ObjectiveTo assess whether responses to tiotropium Respimat add-on therapy were influenced by patients' T2 status.MethodsIn this exploratory study, data from 4 phase III trials were analyzed: once-daily tiotropium 5 μg or placebo as add-on to ICS + LABA (PrimoTinA-asthma; 2 replicate trials; NCT00772538/NCT00776984; n = 912); once-daily tiotropium 5 μg or 2.5 μg, twice-daily salmeterol 50 μg, or placebo as add-on to ICS (MezzoTinA-asthma; 2 replicate trials; NCT01172808/NCT01172821; n = 2100). The prespecified efficacy outcomes of these studies have been reported previously. Here, further exploratory subgroup analyses were performed to study whether these coprimary end points were influenced by serum IgE levels, blood eosinophil counts, and clinician judgment of allergic asthma. In addition, for the continuous parameters, namely, IgE and blood eosinophils, their influence on the treatment effect was modeled over the whole range of values.ResultsTiotropium was efficacious in improving peak FEV1 within 3 hours postdose and trough FEV1, independent of T2 status. Tiotropium significantly reduced the risk of severe asthma exacerbations and asthma worsening, independent of T2 phenotype; Cox regression modeling supported a beneficial effect of tiotropium on exacerbations, independent of IgE levels or eosinophil counts. Numerical improvements in the 7-question Asthma Control Questionnaire (ACQ-7) responder rate with tiotropium versus placebo were observed in T2high and T2low patients; logistic regression modeling provided further evidence for improvement in ACQ-7 responder rates with tiotropium, independent of IgE levels or eosinophil counts.ConclusionsThe results of our exploratory analyses suggest that the improvements seen with tiotropium Respimat as add-on to ICS ± LABA in patients with symptomatic asthma on lung function, exacerbation risk, and symptom control are independent of T2 phenotype. Adding tiotropium to existing inhaled corticosteroid (ICS) maintenance therapy with or without a long-acting β2-agonist (LABA) has been shown to be beneficial in patients with symptomatic asthma. To assess whether responses to tiotropium Respimat add-on therapy were influenced by patients' T2 status. In this exploratory study, data from 4 phase III trials were analyzed: once-daily tiotropium 5 μg or placebo as add-on to ICS + LABA (PrimoTinA-asthma; 2 replicate trials; NCT00772538/NCT00776984; n = 912); once-daily tiotropium 5 μg or 2.5 μg, twice-daily salmeterol 50 μg, or placebo as add-on to ICS (MezzoTinA-asthma; 2 replicate trials; NCT01172808/NCT01172821; n = 2100). The prespecified efficacy outcomes of these studies have been reported previously. Here, further exploratory subgroup analyses were performed to study whether these coprimary end points were influenced by serum IgE levels, blood eosinophil counts, and clinician judgment of allergic asthma. In addition, for the continuous parameters, namely, IgE and blood eosinophils, their influence on the treatment effect was modeled over the whole range of values. Tiotropium was efficacious in improving peak FEV1 within 3 hours postdose and trough FEV1, independent of T2 status. Tiotropium significantly reduced the risk of severe asthma exacerbations and asthma worsening, independent of T2 phenotype; Cox regression modeling supported a beneficial effect of tiotropium on exacerbations, independent of IgE levels or eosinophil counts. Numerical improvements in the 7-question Asthma Control Questionnaire (ACQ-7) responder rate with tiotropium versus placebo were observed in T2high and T2low patients; logistic regression modeling provided further evidence for improvement in ACQ-7 responder rates with tiotropium, independent of IgE levels or eosinophil counts. The results of our exploratory analyses suggest that the improvements seen with tiotropium Respimat as add-on to ICS ± LABA in patients with symptomatic asthma on lung function, exacerbation risk, and symptom control are independent of T2 phenotype." @default.
• W2768245655 created "2017-12-04" @default.
• W2768245655 creator A5010213748 @default.
• W2768245655 creator A5013428765 @default.
• W2768245655 creator A5020646722 @default.
• W2768245655 creator A5022845882 @default.
• W2768245655 creator A5027731238 @default.
• W2768245655 creator A5069959810 @default.
• W2768245655 creator A5079069521 @default.
• W2768245655 creator A5090062530 @default.
• W2768245655 date "2018-05-01" @default.
• W2768245655 modified "2023-09-27" @default.
• W2768245655 title "Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype" @default.
• W2768245655 cites W1487680918 @default.
• W2768245655 cites W1730980153 @default.
• W2768245655 cites W1932569518 @default.
• W2768245655 cites W1991243795 @default.
• W2768245655 cites W2009191674 @default.
• W2768245655 cites W2021865521 @default.
• W2768245655 cites W2022564653 @default.
• W2768245655 cites W2043990114 @default.
• W2768245655 cites W2046179969 @default.
• W2768245655 cites W2064799866 @default.
• W2768245655 cites W2071252658 @default.
• W2768245655 cites W2071270488 @default.
• W2768245655 cites W2074234735 @default.
• W2768245655 cites W2084958270 @default.
• W2768245655 cites W2086714187 @default.
• W2768245655 cites W2097278538 @default.
• W2768245655 cites W2111609315 @default.
• W2768245655 cites W2117993701 @default.
• W2768245655 cites W2119147796 @default.
• W2768245655 cites W2138724153 @default.
• W2768245655 cites W2142158607 @default.
• W2768245655 cites W2144555615 @default.
• W2768245655 cites W2147026486 @default.
• W2768245655 cites W2148583736 @default.
• W2768245655 cites W2152288064 @default.
• W2768245655 cites W2153300494 @default.
• W2768245655 cites W2162590783 @default.
• W2768245655 cites W2184063809 @default.
• W2768245655 cites W2289833205 @default.
• W2768245655 cites W2338443462 @default.
• W2768245655 cites W2394523762 @default.
• W2768245655 cites W2431068257 @default.
• W2768245655 cites W2471100994 @default.
• W2768245655 cites W2515998798 @default.
• W2768245655 cites W2546744840 @default.
• W2768245655 cites W2587152716 @default.
• W2768245655 doi "https://doi.org/10.1016/j.jaip.2017.08.037" @default.
• W2768245655 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29174062" @default.
• W2768245655 hasPublicationYear "2018" @default.
• W2768245655 type Work @default.
• W2768245655 sameAs 2768245655 @default.
• W2768245655 citedByCount "62" @default.
• W2768245655 countsByYear W27682456552018 @default.
• W2768245655 countsByYear W27682456552019 @default.
• W2768245655 countsByYear W27682456552020 @default.
• W2768245655 countsByYear W27682456552021 @default.
• W2768245655 countsByYear W27682456552022 @default.
• W2768245655 countsByYear W27682456552023 @default.
• W2768245655 crossrefType "journal-article" @default.
• W2768245655 hasAuthorship W2768245655A5010213748 @default.
• W2768245655 hasAuthorship W2768245655A5013428765 @default.
• W2768245655 hasAuthorship W2768245655A5020646722 @default.
• W2768245655 hasAuthorship W2768245655A5022845882 @default.
• W2768245655 hasAuthorship W2768245655A5027731238 @default.
• W2768245655 hasAuthorship W2768245655A5069959810 @default.
• W2768245655 hasAuthorship W2768245655A5079069521 @default.
• W2768245655 hasAuthorship W2768245655A5090062530 @default.
• W2768245655 hasBestOaLocation W27682456551 @default.
• W2768245655 hasConcept C126322002 @default.
• W2768245655 hasConcept C141105273 @default.
• W2768245655 hasConcept C142724271 @default.
• W2768245655 hasConcept C151956035 @default.
• W2768245655 hasConcept C159654299 @default.
• W2768245655 hasConcept C203014093 @default.
• W2768245655 hasConcept C204787440 @default.
• W2768245655 hasConcept C27081682 @default.
• W2768245655 hasConcept C2776042228 @default.
• W2768245655 hasConcept C2776719499 @default.
• W2768245655 hasConcept C2777037409 @default.
• W2768245655 hasConcept C71924100 @default.
• W2768245655 hasConceptScore W2768245655C126322002 @default.
• W2768245655 hasConceptScore W2768245655C141105273 @default.
• W2768245655 hasConceptScore W2768245655C142724271 @default.
• W2768245655 hasConceptScore W2768245655C151956035 @default.
• W2768245655 hasConceptScore W2768245655C159654299 @default.
• W2768245655 hasConceptScore W2768245655C203014093 @default.
• W2768245655 hasConceptScore W2768245655C204787440 @default.
• W2768245655 hasConceptScore W2768245655C27081682 @default.
• W2768245655 hasConceptScore W2768245655C2776042228 @default.
• W2768245655 hasConceptScore W2768245655C2776719499 @default.
• W2768245655 hasConceptScore W2768245655C2777037409 @default.
• W2768245655 hasConceptScore W2768245655C71924100 @default.
• W2768245655 hasFunder F4320310441 @default.
• W2768245655 hasIssue "3" @default.
• W2768245655 hasLocation W27682456551 @default.

• next